Victory Capital Management Inc. Reduces Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Victory Capital Management Inc. decreased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 4.1% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 97,794 shares of the medical research company’s stock after selling 4,160 shares during the quarter. Victory Capital Management Inc.’s holdings in IQVIA were worth $23,174,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in IQV. 1832 Asset Management L.P. grew its holdings in shares of IQVIA by 472.3% during the second quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock worth $96,487,000 after purchasing an additional 376,595 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of IQVIA during the second quarter worth about $70,610,000. Impax Asset Management Group plc grew its holdings in shares of IQVIA by 19.3% during the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock worth $344,998,000 after buying an additional 264,555 shares during the last quarter. Canada Pension Plan Investment Board grew its holdings in shares of IQVIA by 6.6% during the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock worth $719,634,000 after buying an additional 211,653 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. grew its holdings in shares of IQVIA by 285.1% during the second quarter. D. E. Shaw & Co. Inc. now owns 268,552 shares of the medical research company’s stock worth $56,783,000 after buying an additional 198,808 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Trading Down 0.8 %

Shares of IQVIA stock opened at $191.19 on Tuesday. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The company has a market capitalization of $34.70 billion, a P/E ratio of 25.09, a P/E/G ratio of 1.98 and a beta of 1.51. The business has a 50 day moving average price of $225.96 and a 200 day moving average price of $228.02.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. The trade was a 6.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 1.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on IQV. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Evercore ISI lowered their price target on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Barclays reduced their price objective on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Morgan Stanley reduced their price objective on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Finally, TD Cowen reduced their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Five investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $259.13.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.